Anal cancer

This MedLibrary.org supplementary page on Anal cancer is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Anal cancer
Classification and external resources
ICD-10 C21.
MeSH D001005

Anal cancer is a type of cancer which arises from the anus, the distal orifice of the gastrointestinal tract. It is a distinct entity from the more common colorectal cancer. The etiology, risk factors, clinical progression, staging, and treatment are all different. Anal cancer is typically a squamous cell carcinoma that arises near the squamocolumnar junction.

Contents

Risk factors

  • Human papillomavirus (HPV) infection: An examination of squamous cell carcinoma tumor tissues from patients in Denmark and Sweden showed a high proportion of anal cancers to be positive for the types of HPV that are also associated with high risk of cervical cancer (90% of the tumors from women, 100% of the tumors from homosexual men, and 58% of tumors from heterosexual men).[1] In another study done, high-risk types of HPV, notably HPV-16, were detected in 84 percent of anal cancer specimens examined.[2]
  • Sexual activity: Having multiple sex partners or having anal sex, due to the increased risk of exposure to the HPV virus.[3]
  • Smoking: Current smokers are several times more likely to develop anal cancer compared with nonsmokers.[3]
  • Immunosuppression, which is often associated with HIV infection.[3]
  • Benign anal lesions. (inflammatory bowel disease (IBD)[4], hemorrhoids, fistulae or cicatrices) Inflammation resulting from benign anal lesions, such as hemorrhoids and anal fistulas, has been considered to cause a predisposition to anal cancer [5] [6]
  • Men who have sex with men are 17 times more likely to develop anal cancer than men who do not have sex with men.[7]

Prevention

Since many, if not most, anal cancers derive from Human Papilloma Virus infections, and since the HPV vaccine prevents infection by several strains of the virus, scientists surmise that HPV vaccination will prevent anal cancer. [8]

Screening

Anal pap smears similar to those used in cervical cancer screening have been studied experimentally for early detection of anal cancer in high-risk individuals.[9][10]

Treatment

Localized disease

Anal cancer is most effectively treated with surgery, and in early stage disease (i.e., localized cancer of the anus without metastasis to the inguinal lymph nodes), surgery is often curative. The difficulty with surgery has been the necessity of removing the anal sphincter, with concomitant fecal incontinence. For this reason, many patients with anal cancer have required permanent colostomies.

In more recent years, physicians have employed a combination strategy including chemotherapy and radiation treatments to reduce the necessity of debilitating surgery. This "combined modality" approach has led to the increased preservation of an intact anal sphincter, and therefore improved quality of life after definitive treatment. Survival and cure rates are excellent, and many patients are left with a functional sphincter. Some patients have fecal incontinence after combined chemotherapy and radiation. Biopsies to document disease regression after chemotherapy and radiation were commonly advised, but are not as frequent any longer. Current chemotherapy active in anal cancer includes cisplatin and 5-FU; mitomycin has also been used, but is associated with increased toxicity.

Metastatic or recurrent disease

Up to 10% of patients treated for anal cancer will develop distant metastatic disease. Metastatic or recurrent anal cancer is difficult to treat, and usually requires chemotherapy. Radiation is also employed to palliate specific locations of disease that may be causing symptoms. Chemotherapy commonly used is similar to other squamous cell epithelial neoplasms, such as platinum analogues, anthracyclines such as doxorubicin, and antimetabolites such as 5-FU and capecitabine. J.D. Hainsworth developed a protocol that includes Taxol and Carboplatinum along with 5-FU.

Prognosis


See also

References

  1. ^ Danish Medical Bulletin. 2002 Aug;49(3):194-209
  2. ^ New England Journal of Medicine. 1997 Nov 6;337(19):1350-8
  3. ^ a b c American Cancer Society. "What Are the Risk Factors for Anal Cancer?"
  4. ^ M Frisch and C Johansen (2000). "Anal carcinoma in inflammatory bowel disease". Anal carcinoma in inflammatory bowel disease. Retrieved on 2008-01-22.
  5. ^ "Carcinoma of the Anus Management" (2007). Retrieved on 2008-01-22.
  6. ^ "Benign Anal Lesions and the Risk of Anal Cancer" (1994). Retrieved on 2008-01-22.
  7. ^ "STD Facts - HPV and Men". Retrieved on 2007-08-17.
  8. ^ Template:Http://www.iht.com/articles/2007/01/31/healthscience/sncancer.php
  9. ^ Cichoki, Mark. "Anal Papilloma Screening" on About.com
  10. ^ Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H (2006). "Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review". Clin. Infect. Dis. 43 (2): 223–33. doi:10.1086/505219. PMID 16779751. 

External links

Wikipedia content modification information:

  • This page was last modified on 10 October 2008, at 02:16.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Anal cancer".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.